In Vitro Drug Metabolism Studies Services

In vitro metabolism studies can exclude the interference of the body factors for the overall experiment to provide a reliable theoretical basis for the low metabolic rate in vivo, toxic and lack of sensitive detection means of drugs, in vitro metabolism research is a good means of research. At present, in vitro models of drug metabolism include microsomal models, gene recombination enzyme models, hepatocyte models, hepatobiliary perfusion models, Liver tissue sections and so on.

Metabolic stability is a key drug property, which is important for both drug administration regiment design as well as toxicity. Species comparison in metabolic stability allows the determination of which animal species is the most appropriate model for the estimation of human metabolic stability of the test article. The use of liver microsomes allows the evaluation of metabolic stability as results of phase I oxidation. The use of hepatocytes allows the evaluation of both phase I oxidation and phase II conjugation.

Medicilon pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and Bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai Government.

Available Studies Include

– Method Development and Validation (GLP & Non-GLP)
– Bioanalysis
– Pharmacokinetics (Tumor bearing rodents, bioavailability, crossover studies, cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration)
– Stability in Vehicles and Plasma
– Drug Interaction Studies
– In vitro Metabolic Stability
– Prediction and Identification of Major Metabolites
– Toxic Kinetics Analysis
– Distribution Studies

Related Articles:

Cancer Metabolism Link with Breast Cancer Oncogene

Metabolic Stability Studies

Drug Metabolism Test of Medicilon

Drug Metabolism and Pharmacokinetics (DMPK) Studies

Contact Us:

Email: marketing@medicilon.com

Tel: +68 02158591500

Website: www.medicilon.com

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

Shanghai Medicilon Inc.

搜索此博客